Sutro Biopharma Debt to Equity

Sutro Biopharma (STRO) currently reports a debt-to-equity ratio of -0.17. That is below the Healthcare sector average of 0.31. Use the charts on this page to explore Sutro Biopharma's debt-to-equity ratio history and peer comparisons.

Sutro Biopharma's debt-to-equity ratio of -0.17 is lower than the Healthcare sector average of 0.31. That is roughly 154.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Sutro Biopharma's market price to a fundamental measure such as earnings, sales, or book value. At -0.17, STRO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of -0.17, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.31. From there, open related valuation or income-statement pages for Sutro Biopharma, and consider following STRO for alerts when major investors trade the stock.

Sutro Biopharma is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows -0.17 versus a sector average near 0.31. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing STRO with unrelated industries.